Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation.

S. Michael Marcy a, Katrin S. Kohl b,∗, Ron Dagan c, David Nalin d, Michael Blum e, Marcy Connell Jones f, John Hansen g, Jerry Labadie h, Lucia Lee i, Bryan L. Martin j, Katherine O’Brien k, Edward Rothstein l, Patricia Vermeer m, The Brighton Collaboration Fever Working Group n, o, 1 a Harbor-UCLA Medical Center, USA and Kaiser-Permanente Health Care Program, CA, USA b Centers for Disease Control and Prevention, National Immunization Program, 1600 Clifton Rd., Mailstop E-61, Atlanta, GA 30333, USA c Soroka Medical Center, Beer Sheva, Israel d Merck & Co., West Point, PA, USA e Wyeth Research, Collegeville, PA, USA f California DHS Immunization Branch, Berkeley, CA, USA g Kaiser Permanente Health Care Program, Oakland, CA, USA h Netherlands Pharmacovigilance Centre Lareb, s-Hertogenbosch, The Netherlands i Food and Drug Administration, Rockville, MD, USA j Walter Reed Army Medical Center, Washington, DC, USA k The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA l Pennridge Pediatrics Associates, Sellersville, PA, USA m National Institute of Public Health and Environment, Bilthoven, The Netherlands n Centers for Disease Control and Prevention, Atlanta, GA, USA o University Children’s Hospital, Basel, Switzerland